A Study of GDC-0810 versus Fulvestrant in Postmenopausal Women with Advanced or Metastatic ER+/HER2- Breast Cancer Resistant To Aromatase Inhibitor Therapy

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-000106-19

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

• To evaluate the efficacy of GDC-0810 compared with fulvestrant in the intent to treat (ITT) population as measured by progression free survival (PFS) • To evaluate the efficacy of GDC-0810 compared with fulvestrant in the estrogen receptor 1 (ESR1) mutant population as measured by PFS


Critère d'inclusion

  • Advanced or Metastatic ER+/HER2- Breast Cancer